Event Date/Time: Dec 06, 2010
End Date/Time: Dec 06, 2010
No single factor influences profits more than price. Accordingly, it is imperative to develop an effective pricing strategy early in the product life cycle. However, an optimal price for reimbursement / market access in one market may not be optimal in others and the pervasiveness of international price referencing and parallel trade creates pressures for price convergence often at sub-optimal levels in key markets. Moreover, health technology assessment (HTA) agencies have taken on increasingly important roles in assessing clinical and cost effectiveness and their assessments have spawned a new environment of risk sharing agreements and patient access schemes. By starting early (i.e., well before market authorisation) it is possible to build effective strategies that establish optimal prices by market, provide evidence to maximise reimbursement, and mitigate the effects of price referencing and parallel trade.
Why should you attend this event?
Upon completion of this MasterClass, attendees will have an understanding of:
Global pricing and reimbursement elements and principles
Pricing theory and research methods
Latest information on the expected changes in the UK (NICE, PPRI, SMC)
P&R/HTA in major EU markets and Canada
Launch sequencing, price corridors